The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company.
The microbiome is ever more frequently spoken about of late, and so the pharmaphorum podcast invited Leo Grady, founder and CEO of Jona, to speak about at-home personal microbiome profiling
Gastrointestinal disease specialist Ironwood Pharma has agreed a $1 billion deal to buy VectivBio and its drug candidate for short bowel syndrome (SBS), betting on positiv
Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndr
Mahana Therapeutics has raised second-round financing of $61 million that will be used to launch what it says will be the first prescription digital therapeutic (DTx) for
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year